MLAB
Bearish signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Mesa Laboratories, Inc.
- Nom
- Mesa Laboratories, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Specialties
- Bourse
- NASDAQ
- Capitalisation
- $720.0M
- Employés
- 717
- PDG
- Siddhartha C. Kadia
- Site web
- https://www.mesalabs.com
- Marché
- ABIOLABMRVIPACBQGEN
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 900 titres (~102 321,00 $ US) VENTE TOTALE: 7 093 titres (~800 090,40 $ US)
- Insiders
- Sullivan John JamesTripeny R Tony
- Total bought
-
$102,321
Avg buy (VWAP, 90d window) $113.69 vs last close —
- Total sold
-
$800,090
Avg sell (VWAP, 90d window) $112.80 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-13 | Sullivan John James | Sell · S | 7,093 | $112.80 | $800,090 | Form 4 |
| 2026-08-13 | Tripeny R Tony | Buy · P | 900 | $113.69 | $102,321 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-26 Drivers: fundamentals. Moteurs : fondamentaux.
MLAB presents a weak investment case with a low catalyst score (15) driven by dominant insider selling and the absence of any meaningful event-driven trigger, compounded by fragile financials marked by high leverage…
The first sentence of the analysis written for MLAB on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Sale value outweighs purchases
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.72 · operating margin 7.4%
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 63.5% | 62.6% | 61.6% | 61.0% | 59.2% | |
| Ebit Margin | 4.8% | 7.4% | -124.9% | 2.0% | 4.0% | |
| Ebitda Margin | 14.2% | 17.6% | -110.3% | 17.1% | 17.6% | |
| Operating Profit Margin | 7.4% | 6.8% | -125.9% | 1.5% | 2.6% | |
| Pretax Profit Margin | 4.8% | 2.5% | -127.5% | -0.2% | 1.9% | |
| Continuous Operations Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Net Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Bottom Line Profit Margin | 2.7% | -0.8% | -117.6% | 0.4% | 1.0% | |
| Current Ratio | 1.717 | 0.626 | 2.468 | 2.744 | 2.587 | |
| Quick Ratio | 1.291 | 0.472 | 1.730 | 1.945 | 2.075 | |
| Solvency Ratio | 0.124 | 0.082 | -0.739 | 0.127 | 0.086 | |
| Cash Ratio | 0.435 | 0.167 | 0.637 | 0.759 | 1.027 | |
| Price To Earnings Ratio | 72.475 | -329.611 | -2.373 | 1,027.824 | 708.000 | |
| Price To Earnings Growth Ratio | -0.165 | 3.321 | 0.000 | -19.475 | -15.576 | |
| Forward Price To Earnings Growth Ratio | -0.165 | 3.321 | 0.000 | -19.475 | -15.576 | |
| Price To Earnings Diluted Ratio | 73.074 | -329.611 | -2.373 | 1,027.824 | 728.229 | |
| Price To Earnings Diluted Growth Ratio | -0.168 | 3.321 | 0.000 | -19.985 | -16.071 | |
| Price To Book Ratio | 2.618 | 4.031 | 4.149 | 2.363 | 3.373 | |
| Price To Sales Ratio | 1.957 | 2.673 | 2.790 | 4.244 | 7.207 | |
| Price To Free Cash Flow Ratio | 12.318 | 15.226 | 14.513 | 39.666 | 38.183 | |
| Price To Operating Cash Flow Ratio | 11.383 | 13.763 | 13.669 | 33.225 | 33.869 | |
| Debt To Assets Ratio | 0.395 | 0.419 | 0.518 | 0.281 | 0.313 | |
| Debt To Equity Ratio | 0.906 | 1.135 | 1.591 | 0.473 | 0.562 | |
| Debt To Capital Ratio | 0.475 | 0.532 | 0.614 | 0.321 | 0.360 | |
| Long Term Debt To Capital Ratio | 0.439 | 0.325 | 0.604 | 0.318 | 0.357 | |
| Financial Leverage Ratio | 2.297 | 2.711 | 3.073 | 1.682 | 1.796 | |
| Working Capital Turnover Ratio | -29.469 | 128.112 | 3.074 | 2.885 | 1.061 | |
| Operating Cash Flow Ratio | 0.692 | 0.285 | 0.996 | 0.645 | 0.816 | |
| Operating Cash Flow Sales Ratio | 0.172 | 0.194 | 0.204 | 0.128 | 0.213 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.924 | 0.904 | 0.942 | 0.838 | 0.887 | |
| Debt Service Coverage Ratio | 1.838 | 0.305 | -38.086 | 8.141 | 7.934 | |
| Interest Coverage Ratio | 1.731 | 1.378 | -47.758 | 0.696 | 1.210 | |
| Short Term Operating Cash Flow Coverage Ratio | 7.614 | 0.463 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.254 | 0.258 | 0.191 | 0.150 | 0.177 | |
| Capital Expenditure Coverage Ratio | 13.179 | 10.404 | 17.192 | 6.158 | 8.850 | |
| Dividend Paid And Capex Coverage Ratio | 6.324 | 5.875 | 7.338 | 3.520 | 5.047 | |
| Dividend Payout Ratio | 0.525 | -1.757 | -0.014 | 3.662 | 1.785 | |
| Enterprise Value Multiple | 17.839 | 18.853 | -3.383 | 28.868 | 46.122 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 63.5% | ▲0.9% | ▲1.9% |
| Ebit Margin | 4.8% | ▼-2.6% | ▲26.1% |
| Ebitda Margin | 14.2% | ▼-3.4% | ▲22.9% |
| Operating Profit Margin | 7.4% | ▲0.7% | ▲28.9% |
| Pretax Profit Margin | 4.8% | ▲2.4% | ▲28.5% |
| Continuous Operations Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Net Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Bottom Line Profit Margin | 2.7% | ▲3.5% | ▲25.6% |
| Current Ratio | 1.717 | ▲1.091 | ▼-0.311 |
| Quick Ratio | 1.291 | ▲0.819 | ▼-0.212 |
| Solvency Ratio | 0.124 | ▲0.042 | ▲0.188 |
| Cash Ratio | 0.435 | ▲0.268 | ▼-0.170 |
| Price To Earnings Ratio | 72.475 | ▲402.087 | ▼-222.788 |
| Price To Earnings Growth Ratio | -0.165 | ▼-3.487 | ▲6.214 |
| Forward Price To Earnings Growth Ratio | -0.165 | ▼-3.487 | ▲6.214 |
| Price To Earnings Diluted Ratio | 73.074 | ▲402.685 | ▼-226.354 |
| Price To Earnings Diluted Growth Ratio | -0.168 | ▼-3.489 | ▲6.413 |
| Price To Book Ratio | 2.618 | ▼-1.413 | ▼-0.689 |
| Price To Sales Ratio | 1.957 | ▼-0.716 | ▼-1.817 |
| Price To Free Cash Flow Ratio | 12.318 | ▼-2.909 | ▼-11.664 |
| Price To Operating Cash Flow Ratio | 11.383 | ▼-2.380 | ▼-9.799 |
| Debt To Assets Ratio | 0.395 | ▼-0.024 | ▲0.010 |
| Debt To Equity Ratio | 0.906 | ▼-0.229 | ▼-0.027 |
| Debt To Capital Ratio | 0.475 | ▼-0.056 | ▲0.015 |
| Long Term Debt To Capital Ratio | 0.439 | ▲0.114 | ▲0.031 |
| Financial Leverage Ratio | 2.297 | ▼-0.415 | ▼-0.015 |
| Working Capital Turnover Ratio | -29.469 | ▼-157.581 | ▼-50.602 |
| Operating Cash Flow Ratio | 0.692 | ▲0.406 | ▲0.005 |
| Operating Cash Flow Sales Ratio | 0.172 | ▼-0.022 | ▼-0.010 |
| Free Cash Flow Operating Cash Flow Ratio | 0.924 | ▲0.020 | ▲0.025 |
| Debt Service Coverage Ratio | 1.837 | ▲1.533 | ▲5.811 |
| Interest Coverage Ratio | 1.731 | ▲0.354 | ▲10.280 |
| Short Term Operating Cash Flow Coverage Ratio | 7.614 | ▲7.151 | ▲5.999 |
| Operating Cash Flow Coverage Ratio | 0.254 | ▼-0.004 | ▲0.048 |
| Capital Expenditure Coverage Ratio | 13.179 | ▲2.775 | ▲2.022 |
| Dividend Paid And Capex Coverage Ratio | 6.324 | ▲0.449 | ▲0.703 |
| Dividend Payout Ratio | 0.525 | ▲2.282 | ▼-0.315 |
| Enterprise Value Multiple | 17.839 | ▼-1.014 | ▼-3.821 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $487.5M | $644.2M | $603.2M | $929.7M | $1.33B | |
| Enterprise value | $629.5M | $798.4M | $806.3M | $1.08B | $1.50B | |
| EV / Sales | 2.53x | 3.31x | 3.73x | 4.94x | 8.14x | |
| EV / Op. cash flow | 14.70x | 17.06x | 18.27x | 38.70x | 38.25x | |
| EV / Free cash flow | 15.90x | 18.87x | 19.40x | 46.20x | 43.12x | |
| EV / EBITDA | 17.84x | 18.85x | -3.38x | 28.87x | 46.12x | |
| Net debt / EBITDA | 4.02x | 3.64x | -0.85x | 4.08x | 5.28x | |
| Current ratio | 1.72x | 0.63x | 2.47x | 2.74x | 2.59x | |
| Income quality | 6.38x | -23.71x | -0.17x | 30.09x | 20.96x | |
| Graham number | $30 | — | — | $17 | $25 | |
| Graham net-net | -$31 | -$37 | -$42 | -$35 | -$42 | |
| Tax burden | 55.9% | -33.1% | 92.2% | -239.1% | 52.4% | |
| Interest burden | 100.0% | 33.5% | 102.1% | -8.9% | 47.9% | |
| Working capital | $44.4M | -$61.3M | $65.0M | $75.6M | $76.3M | |
| Invested capital | $362.7M | $249.7M | $400.3M | $607.0M | $646.2M | |
| Return on assets | 1.6% | -0.5% | -56.9% | 0.1% | 0.3% | |
| Operating ROA | 4.3% | 3.7% | -49.1% | 0.5% | 0.7% | |
| Return on tangible assets | 4.3% | -1.3% | -166.2% | 0.6% | 1.1% | |
| Return on equity | 3.6% | -1.2% | -174.9% | 0.2% | 0.5% | |
| Return on invested capital | 2.8% | -1.4% | -61.9% | -1.3% | 0.4% | |
| Return on capital employed | 5.1% | 6.1% | -67.6% | 0.5% | 0.7% | |
| Earnings yield | 1.4% | -0.3% | -42.1% | 0.1% | 0.1% | |
| Free cash flow yield | 8.1% | 6.6% | 6.9% | 2.5% | 2.6% | |
| Capex / Op. cash flow | 7.6% | 9.6% | 5.8% | 16.2% | 11.3% | |
| Capex / Depreciation | 14.0% | 18.3% | 8.1% | 13.7% | 17.7% | |
| Capex / Sales | 1.3% | 1.9% | 1.2% | 2.1% | 2.4% | |
| SG&A / Sales | 47.9% | 47.7% | 51.6% | 50.2% | 48.1% | |
| R&D / Sales | 8.2% | 8.1% | 8.9% | 9.4% | 8.6% | |
| Stock comp / Sales | 7.2% | 5.5% | 5.5% | 5.7% | 6.2% | |
| Intangibles / Total assets | 63.2% | 64.3% | 65.8% | 76.0% | 76.5% | |
| Days sales outstanding | 65d | 64d | 66d | 71d | 82d | |
| Days payables outstanding | 20d | 23d | 27d | 26d | 38d | |
| Operating cycle | 171d | 166d | 210d | 219d | 201d | |
| Cash conversion cycle | 151d | 143d | 183d | 193d | 163d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-10 Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
- 2026-08-10 Mesa Laboratories Q1 Earnings Call Highlights Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
- 2026-08-03 Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
- 2026-07-06 MESA LABS DECLARES QUARTERLY DIVIDEND Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.
- 2026-05-27 Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street''s expected earnings, but the business did report strong growth for adjusted operating income.
- 2026-05-27 Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands).